ArticleAmerican health & drug benefits2013
The incidence rate and economic burden of community-acquired pneumonia in a working-age population.
Article in American health & drug benefits, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 3 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Costs of management of acute respiratory infections in older adults: A systematic review and meta-analysis.Journal of global health · 2022Pooled it
- Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients.The Cochrane database of systematic reviews · 2018Pooled it
- Systematic Review and Meta-analysis of the Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia in Adults.Antimicrobial agents and chemotherapy · 2018Pooled it
- Trial
- Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial.BMC infectious diseases · 2017Trial
- Consultations, (antibiotic) prescriptions, and productivity losses of patients with community-acquired respiratory tract infection: country-specific findings from the PRUDENCE trial.The European journal of health economics : HEPAC : health economics in prevention and care · 2026Article
- Observational
- Burden of Invasive Pneumococcal Disease and Community-Acquired Pneumonia in Adults: Significant Adverse Outcomes and Costs beyond Direct Treatment.Infectious diseases and therapy · 2026Article
- Health disparities in the burden of pneumococcal disease in US adults.Pneumonia (Nathan Qld.) · 2026Review
- Purulent pericarditis and cardiac tamponade in HIV: a case report on a dreaded complication ofAnnals of medicine and surgery (2012) · 2024Article
- The value of surfactant protein a in evaluating the severity and prognosis in community-acquired pneumonia patients.BMC pulmonary medicine · 2024Article
- Characterization of Markers in Blood Tests of Patients With Pleural Effusion and Their Correlation to Different Etiologies.Journal of community hospital internal medicine perspectives · 2024Article
- Identifying Risk Factors for Aspiration in Patients Hospitalized with Community-Acquired Pneumonia.International journal of clinical practice · 2023Article
- Neutrophil trafficking to the site of infection requires Cpt1a-dependent fatty acid β-oxidation.Communications biology · 2022Article
- Airway Prevotella promote TLR2-dependent neutrophil activation and rapid clearance of Streptococcus pneumoniae from the lung.Nature communications · 2022Article
- Characterizing the Occurrence of Key Clinical Milestones in Duchenne Muscular Dystrophy in the United States Using Real-World Data.Journal of neuromuscular diseases · 2022Article
- Serum interleukin-17 predicts severity and prognosis in patients with community acquired pneumonia: a prospective cohort study.BMC pulmonary medicine · 2021Article
- Biomarker Value in the Diagnosis of Community-Acquired Pneumonia with Concomitant Chronic Heart Failure.Journal of clinical medicine · 2021Article
- Characterizing demographics, comorbidities, and costs of care among populations with Duchenne muscular dystrophy with Medicaid and commercial coverage.Journal of managed care & specialty pharmacy · 2021Article
- The Role of Pneumococcal Pneumonia among Community-Acquired Pneumonia in Adult Turkish Population: TurkCAP Study.Turkish thoracic journal · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCommunity-acquired pneumonia (CAP) is frequently associated with the very young and the elderly but is a largely underrecognized burden among working-age adults. Although the burden of CAP among the elderly has been established, there are limited data on the economic burden of CAP in the employed population.
objectiveTo assess the economic impact of CAP in US working-age adults from an employer perspective by estimating the incidence rate and costs of healthcare, sick time, and short-term disability for this patient population.
methodsThis retrospective cohort study is based on data from 2 Truven Health Analytics databases. The study population consisted of commercially insured active employees aged 18 to 64 years, early retirees aged <65 years, and adult dependents of both cohorts. CAP was identified using medical claims with pneumonia diagnosis codes during the 2009 calendar year. Incidence rate, episode level, and annual costs were stratified by age and by risk based on the presence of comorbidities. Descriptive statistics were used to compare healthcare (ie, medical and pharmacy) costs, sick time, and short-term disability costs between the cohorts with and without CAP. Linear regression was used to estimate the average annual incremental healthcare cost in employed patients with inpatient or outpatient CAP versus individuals without CAP.
resultsStudy eligibility was met by 12,502,017 employed individuals, including 123,920 with CAP and 12,378,097 without CAP; the overall incidence rate of CAP was 10.6 per 1000 person-years. Among individuals with and without CAP, the costs of healthcare, sick time, and short-term disability increased with advancing age and with higher risk status. The mean annual healthcare costs were $20,961 for patients with CAP and $3783 for individuals without CAP. Overall, the mean costs of sick time and short-term disability were $1129 and $1016, respectively, in active employees with CAP, and $853 and $322, respectively, in their counterparts without CAP. Compared with individuals without CAP, the average annual incremental healthcare cost ranged from $39,889 to $113,837 for inpatient management of patients with CAP and from $4170 to $31,524 for outpatient management of patients with CAP, depending on the risk level.
conclusionsCAP is a common and costly infection among working-age individuals, especially in patients with comorbidities. Prevention strategies, such as influenza and pneumococcal vaccination, that target working-age adults with underlying medical conditions may be the most valuable in reducing the morbidity and costs associated with CAP.
Identifiers
24991378PMC4031734W2111278463What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.